IBA announces high level production results achieved by its cyclotron at UZ Brussel

RadioPharma Solutions
/
19.06.2018

The IBA Cyclone® KIUBE 300 has the highest production capacity ever reached by a PET cyclotron with its ability to produce up to 300 FDG* doses in a 2-hour run.

Louvain-la-Neuve, Belgium, June 18th 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, today announces high level production results achieved by its fixed-energy cyclotron, the Cyclone® KIUBE 300µA, installed at the University Hospital UZ Brussel in Belgium.

IBA’s Cyclone® KIUBE was quickly established as the mid-energy cyclotron of choice after its launch due to its high production capacity and compact size. Cyclone® KIUBE is a true evolutionary cyclotron, meaning that production capacity can be increased step-by-step: from 10, 16, 20 to reach 30 Curies (1110 GBq) of F-18 in a two-hour run, enabling the PET centers to meet the increasing demand for fluorodeoxyglucose (“FDG”), a key element in clinical PET imaging.

Bruno Scutnaire, Head of RadioPharma Solutions at IBA, commented: “Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time and to produce numerous other compounds the same day. Short-lived isotopes used in PET cannot be stockpiled and must be produced daily. The Cyclone® KIUBE 300 is the perfect solution with its ability to produce large batches of FDG while offering a large panel of targets and chemistry solutions for non-conventional radioisotope production.”

“We selected IBA’s Cyclone® KIUBE 300 because it is the highest production capacity cyclotron in the market and it has two independent ion sources,” said Dr Tony Lahoutte, Head of the Nuclear Medicine Department at UZ Brussel. “It allows us to answer the increasing demand of FDG while saving time for other isotope production with its eight exit ports.”

“We are impressed by the reliability of our Cyclone® KIUBE. The interface is user-friendly and simple to use and we can rely on the automatic production mode to deliver the required quantities of F-18.”said Vicky Caveliers,Head of Radiopharmacy at UZ Brussel.

*fluorodeoxyglucose labelled with F-18 is the most commonly used radiotracer in positron emission molecular imaging.

 

***ENDS***

About the Cyclone® KIUBE
Cyclone® KIUBE is a fixed-energy cyclotron that accelerates negative ions up to 18 MeV and that host up to two proton sources. Designed to deliver, Cyclone® KIUBE offers the highest production capacity ever reached with a PET cyclotron. It will be able to produce up to 300 FDG doses in a 2-hour run. Designed for you, Cyclone® KIUBE is also available with a self-shielding option. Designed for ever, Cyclone® KIUBE is upgradable like no other cyclotron, so you can increase your production capacity. A full range of Nirta® targets are available giving you access to 18F, 13N, 15O, 11C , 18F2, 68Ga. For more info, please visit our website: https://www.iba-radiopharmasolutions.com/products/cyclotrons#cyclone-kiube

 

About IBA Radiopharma Solutions
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

 

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered  the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

 

About UZ Brussels
The radiopharmaceutical chemistry unit is part of the Nuclear Medicine department of the UZ Brussel and aims at the synthesis and production of both routine and newly developed radiolabelled molecules for the diagnosis and (therapy) of various disease. The radiopharmacy is directly linked with the cyclotron unit giving access to daily productions of cyclotron-based radioisotopes. UZ Brussel is part of the Brussels Imaging Pharmacy (BIP) and the Brussels RadioTheranostics Platform (BRTP), an established coordinated network of radiopharmacists, radiochemists, scientists and clinicians of 3 hospitals -UZ Brussel, IJ Bordet and ULB Erasme- in the Brussels region.

The availability of a wide range of diagnostic radiopharmaceuticals allows for more accurate and specific diagnosis and follow-up of patients. The development of targeted tracers for radionuclide therapy will offer more individualized patient treatment.

For further information, please contact:

IBA
Rebecca lo bue
Marketing Director
+32 10 201 245
Rebecca.lobue@iba-group.com

Share
Download